Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Plaque and Guttate Psoriasis
NCT04645355Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Mar 2021
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of guselkumab in guttate psoriasis and plaque psoriasis (2 arms), sponsored by University of California, San Francisco. Primary endpoints: Lesional CD4+ T Effector Cells at week 12 and Lesional CD8+ T Effector Cells at week 12. Started Mar 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
guttate psoriasisplaque psoriasis
Beyond the preview
Go deeper on NCT04645355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645355.